Piper Jaffray Starts Celyad SA (CYAD) at Overweight
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/11/2026
- S&P 500 muted as industrials counter tech drag; US-Iran peace prospects rise
- S&P 500 EPS growth above 20% is rare. Why 2027 may be at risk
- Goldman Sachs warns AI investment may be crowding out other business spending
- Why Wednesday's inflation print could provide the next dovish catalyst
- Tesla needs Robotaxi flywheel proof to boost investor conviction: Morgan Stanley
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
- After-Hours Movers: SPCX, AMD, ANET, PINS, APPS, UPST, ZETA, BKNG, LCID, CPNG, MTCH
- After-Hours Stock Movers: PLTR, SNAP, ON, ICHR, WGS, WHR
UPDATE: UBS Starts Celyad SA (CYAD) at Buy
July 14, 2015 8:22 AM EDT(Updated - July 14, 2015 8:43 AM EDT)
UBS initiates coverage on Celyad SA (NASDAQ: CYAD) with a Buy rating and a price target of $82.00.
Analyst Andrew Peters commented, "We are initiating coverage on Celyad SA with a Buy rating and $82 price target following an extensive analysis of the phase-3 C-Cure program in heart failure as well as the NK-based CAR-T technology currently in phase-1 trials. We believe initial proofof-concept data from... More
